GBG Forschungs GmbH (German Breast Group)

Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome (2022) Sinn BV, Untch M, Karn T, Van Mackelenbergh M, Huober J, Sychra K, Schmitt WD, et al. Conference contribution Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC) (2022) Reinisch M, Blohmer JU, Link T, Just M, Untch M, Stoetzer O, Fasching P, et al. Conference contribution Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference (2022) Kolberg-Liedtke C, Lueftner D, Brucker SY, Budach W, Denkert C, Fasching P, Haidinger R, et al. Journal article Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial (2022) Gerber B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, et al. Journal article AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. (2022) Ditsch N, Woecke A, Untch M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, et al. Journal article, Review article AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. (2022) Thill M, Lueftner D, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, et al. Journal article, Review article Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients with Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial (2022) Blohmer JU, Link T, Reinisch M, Just M, Untch M, Stotzer O, Fasching P, et al. Journal article DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status (2021) Jurmeister P, Weber K, Villegas S, Karn T, Untch M, Thieme A, Mueller V, et al. Journal article Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer (BMC Cancer, (2021), 21, 1, (920), 10.1186/s12885-021-08656-0) (2021) Stuerken C, Moebus V, Milde-Langosch K, Schmatloch S, Fasching P, Rueschoff J, Stickeler E, et al. Journal article, Erratum AGO Algorithms for the Treatment of Breast Cancer: Update 2021 AGO-Algorithmen zur Behandlung von Brustkrebs: Update 2021 (2021) Schneeweiss A, Fasching P, Fehm T, Gerber B, Jackisch C, Loibl S, Schmidt M, et al. Journal article